CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Opioid ligand binding sites in the spinal cord of the guinea-pig
Authors
S. R. Brown
B. M. Cox
Linda L. Werling
G. D. Zarr
Publication date
1 January 1986
Publisher
Health Sciences Research Commons
Abstract
The properties of opioid binding sites in membranes from the spinal cord of the guinea-pig were analyzed in experiments employing radiolabeled opioid ligands, selective or partially selective for μ, δ and k-type binding sites. Incubation was conducted at 37°C in a quasi-physiological modified Krebs medium, containing sodium and magnesium. The types of binding sites were discriminated on the basis of their affinities for [3H]-d-Ala2-MePhe4-Gly5-ol]enkephalin ([3H]DAGO), [3H-d-Ala2-d-Leu5-enkephalin, and [3H]ethyketocyclazocine and the relative potencies of the displacing ligands, DAGO, [d-Ser2-Leu-5]enkephalyl-Thr and tran-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzene-acetamide methanesulfonate hydrate (U50488H), which are selective for μ, δ and k type binding sites respectively. In membranes from whole spinal cord, k type sites comprised about 60%, μ about 30% and δ about 10% of the total of μ, δ and k binding sites. Binding sites of the μ type were also found in the lumbo-sacral region of guinea-pig spinal cord, in contrast to earlier reports of their absence from this tissue. Morphine showed a better than 500-fold selectivity for μ over k sites in spinal cord, while nalbuphine and (-)1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)3-pentanone methanesulfonate (WIN 44441-3) showed about a 10-fold selectivity for μ sites. The drug U50488H had about a 150-fold greater affinity for k than μ-type binding sites. © 1986
Similar works
Full text
Available Versions
George Washington University: Health Sciences Research Commons (HSRC)
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:hsrc.himmelfarb.gwu.edu:sm...
Last time updated on 03/12/2020